银屑病的生物疗法：从临床角度进行的依从性与疗效分析。
Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective.
作者信息
Ross Christopher, Marshman Gillian, Grillo Marianne, Stanford Tyman
机构信息
Department of Dermatology, Flinders Medical Centre, Bedford Park, South Australia, Australia.
Discipline of Statistics, School of Mathematics, University of Adelaide, Adelaide, South Australia, Australia.
出版信息
Australas J Dermatol. 2016 May;57(2):137-40. doi: 10.1111/ajd.12294. Epub 2015 Mar 5.
We evaluated and compared patients' long-term adherence to biological therapies in a real-life clinical setting. Secondary aims included weight changes on biological therapy and reporting adverse effects. This prospective case-note review included 58 patients, undergoing 84 treatment series including etanercept (21), adalimumab (24), infliximab (14) and ustekinumab (25). Patients' adherence was greatest with ustekinumab (being 6.7-fold less likely to withdraw from treatment than etanercept, P = 0.014), while the difference in treatment adherence of adalimumab and infliximab compared to etanercept was not statistically significant. Adalimumab and infliximab were associated with an increase in weight, while ustekinumab was associated with weight loss compared with etanercept (not statistically significant). Long-term patient adherence to biologic therapy in patients with psoriasis is greatest with ustekinumab.
我们在实际临床环境中评估并比较了患者对生物疗法的长期依从性。次要目标包括生物疗法期间的体重变化以及不良反应报告。这项前瞻性病例记录回顾纳入了58例患者，进行了84个治疗疗程，包括依那西普（21例）、阿达木单抗（24例）、英夫利昔单抗（14例）和优特克单抗（25例）。患者对优特克单抗的依从性最佳（退出治疗的可能性比依那西普低6.7倍，P = 0.014），而阿达木单抗和英夫利昔单抗与依那西普相比，治疗依从性的差异无统计学意义。与依那西普相比，阿达木单抗和英夫利昔单抗与体重增加相关，而优特克单抗与体重减轻相关（无统计学意义）。银屑病患者对生物疗法的长期患者依从性以优特克单抗最佳。
Zotero 插件